• Ranbapril indications
• Uses of Ranbapril in details
• Ranbapril description
• Ranbapril dosage
• Ranbapril interactions
• Ranbapril side effects
• Ranbapril contraindications

What is Ranbapril?

Ranbapril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks.

Ranbapril works by blocking a substance in the body that causes the blood vessels to tighten. As a result, Ranbapril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.

Ranbapril is also used in patients with coronary artery disease to prevent heart attacks.

Ranbapril is available only with your doctor's prescription.

Ranbapril indications

Stable Coronary Artery Disease: Reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.

Conventional treatment for management of coronary artery disease eg, antiplatelet, antihypertensive or lipid-lowering therapy.

Hypertension: Treatment of patients with essential hypertension. It may be used alone or given with other classes of antihypertensives, especially thiazide diuretics.

When using Ranbapril, consideration should be given to the fact that another ACE inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether Ranbapril has a similar potential.

In considering use of Ranbapril, it should be noted that in controlled trials, ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, it should be noted that Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-Blacks.

How should I use Ranbapril?

Use Ranbapril as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Ranbapril by mouth with or without food.
• Take Ranbapril on a regular schedule to get the most benefit from it.
• Taking Ranbapril at the same time(s) each day will help you to remember to take it.
• Continue taking Ranbapril even if you feel well. Do not miss any doses.
• If you miss a dose of Ranbapril, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ranbapril.

Uses of Ranbapril in details

Ranbapril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to prevent heart attacks in patients with a certain type of heart disease (stable coronary artery disease).

Ranbapril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This medication may also be used to treat congestive heart failure and to help protect the kidneys from damage due to diabetes.

How to use Ranbapril

Take this medication by mouth as directed by your doctor, usually once or twice daily. The dosage is based on your medical condition and response to treatment.

To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully.

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.

It may take several weeks before you get the full benefit of this drug.

Tell your doctor if your condition does not get better or if it gets worse (for example, your blood pressure readings remain high or increase).

Ranbapril description

Ranbapril is the tert-butylamine salt of Ranbapril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Ranbapril tert-butylamine is chemically described as (2S, 3αS, 7αS)-1-[(S)-N-[(S)-1-Carboxy-butyl] alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). Its molecular formula is C₁₉H₃₂N₂O₅C₄H₁₁N.

Ranbapril tert-butylamine has molecular weight of 368.47 (free acid) or 441.61 (salt form).

Ranbapril is the free acid form of tert-butylamine, is a pro-drug and metabolized in vivo by hydrolysis of the ester group to form perindoprilat, the biologically active metabolite.

Ranbapril dosage

Ranbapril Dosage

Generic name: Ranbapril erbumine 2mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Hypertension

Use in Uncomplicated Hypertensive Patients: In patients with essential hypertension, the recommended initial dose is 4 mg once a day. The dose may be titrated, as needed to a maximum of 16 mg per day. The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses.

Use in Elderly Patients: The recommended initial daily dosage of Ranbapril for the elderly is 4 mg daily, given in one or two divided doses. Experience with Ranbapril is limited in the elderly at doses exceeding 8 mg. Dosages above 8 mg should be administered with careful blood pressure monitoring and dose titration.

Use with Diuretics: In patients who are currently being treated with a diuretic, symptomatic hypotension can occur following the initial dose of Ranbapril. Consider reducing the dose of diuretic prior to starting Ranbapril.

Stable Coronary Artery Disease

In patients with stable coronary artery disease, Ranbapril should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased as tolerated, to a maintenance dose of 8 mg once daily. In elderly patients (greater than 70 years), Ranbapril should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated.

Dose Adjustment in Renal Impairment and Dialysis

Perindoprilat elimination is decreased in renally impaired patients. Ranbapril is not recommended in patients with creatinine clearance <30 mL/min. For patients with lesser degrees of impairment, the initial dosage should be 2 mg/day and dosage should not exceed 8 mg/day. During dialysis, Ranbapril is removed with the same clearance as in patients with normal renal function.

More about Ranbapril (Ranbapril)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 0 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Ranbapril
• Ranbapril (Advanced Reading)

Professional resources

• Ranbapril (AHFS Monograph)
• Ranbapril (FDA)

Related treatment guides

• Coronary Artery Disease
• Diabetic Kidney Disease
• Heart Attack
• Heart Failure
• High Blood Pressure
• More (1) »

Ranbapril interactions

See also:
What other drugs will affect Ranbapril?

Diuretics: Patients on diuretics and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of Ranbapril therapy. The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Ranbapril. If diuretics cannot be interrupted, close medical supervision should be provided with the 1st dose of Ranbapril, for at least 2 hrs and until blood pressure has stabilized for another hour.

The rate and extent of Ranbapril absorption and elimination are not affected by concomitant diuretics. The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.

Potassium Supplements and Potassium-Sparing Diuretics: Ranbapril may increase serum potassium because of its potential to decrease aldosterone production. Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patient's serum potassium should be monitored frequently.

Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be co-administered with caution and frequent monitoring of serum lithium concentration is recommended. Use of a diuretic may further increase the risk of lithium toxicity.

Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Ranbapril.

Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when co-administered with Ranbapril, but an effect of digoxin on the plasma concentration of Ranbapril/perindoprilat has not been excluded.

Gentamicin: Animal data have suggested the possibility of interaction between Ranbapril and gentamicin. However, this has not been investigated in human studies. Co-administration of both drugs should proceed with caution.

Food Interaction:

Oral administration of Ranbapril with food does not significantly lower the rate or extent of Ranbapril absorption relative to the fasted state. However, the extent of biotransformation of Ranbapril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. In clinical trials, Ranbapril was generally administered in a nonfastingstate.

Ranbapril side effects

See also:
What are the possible side effects of Ranbapril?

Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience

The following adverse reactions are discussed elsewhere in labeling:

• Anaphylactoid reactions, including angioedema
• Hypotension
• Neutropenia and agranulocytosis
• Impaired renal function
• Hyperkalemia
• Cough

Hypertension

Ranbapril has been evaluated for safety in approximately 3,400 patients with hypertension in U.S. and foreign clinical trials. The data presented here are based on results from the 1,417 Ranbapril-treated patients who participated in the U.S. clinical trials. Over 220 of these patients were treated with Ranbapril® (Ranbapril erbumine) for at least one year.

In placebo-controlled U.S. clinical trials, the incidence of premature discontinuation of therapy due to adverse events was 6.5% in patients treated with Ranbapril and 6.7% in patients treated with placebo. The most common causes were cough, headache, asthenia and dizziness.

Among 1,012 patients in placebo-controlled U.S. trials, the overall frequency of reported adverse events was similar in patients treated with Ranbapril and in those treated with placebo (approximately 75% in each group). The only adverse events whose incidence on Ranbapril was at least 2% greater than on placebo were cough (12% vs. 4.5%) and back pain (5.8% vs. 3.1%).

Dizziness was not reported more frequently in the Ranbapril group (8.2%) than in the placebo group (8.5%), but its likelihood increased with dose, suggesting a causal relationship with Ranbapril.

Stable Coronary Artery Disease

Ranbapril has been evaluated for safety in EUROPA, a double-blind, placebo-controlled study in 12,218 patients with stable coronary artery disease. The overall rate of discontinuation was about 22% on drug and placebo. The most common medical reasons for discontinuation that were more frequent on Ranbapril than placebo were cough, drug intolerance and hypotension.

Postmarketing Experience

Voluntary reports of adverse events in patients taking Ranbapril that have been received since market introduction and are of unknown causal relationship to Ranbapril include: cardiac arrest, eosinophilic pneumonitis, neutropenia/agranulocytosis, pancytopenia, anemia (including hemolytic and aplastic), thrombocytopenia, acute renal failure, nephritis, hepatic failure, jaundice (hepatocellular or cholestatic), symptomatic hyponatremia, bullous pemphigoid, pemphigus, acute pancreatitis, falls, psoriasis, exfoliative dermatitis and a syndrome which may include: arthralgia/arthritis, vasculitis, serositis, myalgia, fever, rash or other dermatologic manifestations, a positive antinuclear antibody (ANA), leukocytosis, eosinophilia or an elevated erythrocyte sedimentation rate (ESR).

Clinical Laboratory Test Findings

Hematology

Small decreases in hemoglobin and hematocrit occur frequently in hypertensive patients treated with Ranbapril, but are rarely of clinical importance. In controlled clinical trials, no patient was discontinued from therapy due to the development of anemia. Leukopenia (including neutropenia) was observed in 0.1% of patients in U.S. clinical trials.

Liver Function Tests

Elevations in ALT (1.6% Ranbapril versus 0.9% placebo) and AST (0.5% Ranbapril versus 0.4% placebo) have been observed in placebo-controlled clinical trials. The elevations were generally mild and transient and resolved after discontinuation of therapy.

Ranbapril contraindications

See also:
What is the most important information I should know about Ranbapril?

Hypersensitivity to Ranbapril or to any of the excipients of Ranbapril or to any other ACE inhibitor; history of angioedema associated with previous ACE inhibitor therapy; hereditary or idiopathic angioedema.

Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency should not take Ranbapril.

Use in pregnancy: Ranbapril should not be used during the 1st trimester of pregnancy. When a pregnancy is planned or confirmed, the switch to an alternative treatment should be initiated as soon as possible. Controlled studies with ACE inhibitors have not been done in humans, but in a limited number of cases with 1st trimester exposure, there do not appear to have been any malformations consistent with human foetotoxicity as described as follows.

Ranbapril is contraindicated during the 2nd and 3rd trimesters of pregnancy.

Prolonged ACE inhibitor exposure during the 2nd and 3rd trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).

Should exposure to Ranbapril have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Active ingredient matches for Ranbapril:

Perindopril in Serbia.

List of Ranbapril substitutes (brand and generic names)	Sort by popularity
Unit description / dosage (Manufacturer)	Price, USD
Prestoril
Tablet; Oral; Perindopril Erbumine 4 mg
Prestpril (Romania)
Prexanil (Croatia (Hrvatska), Czech Republic, Estonia, Serbia, Slovenia)
Prexanil A (Croatia (Hrvatska))
Prexanil Combi A (Croatia (Hrvatska))
Prexum (Indonesia, South Africa)
Pricoron (Czech Republic, Romania)
Prilam (Georgia)
Prindace (Ireland)
Prindex (Bulgaria, Estonia, Latvia, Lithuania, Romania)
Syrup; Oral; Carbinoxamine Maleate 25 mg; Pseudoephedrine Hydrochloride 60 mg / 5 ml (Medicamenta)
Tablet, Film-Coated; Oral; Carbinoxamine Maleate 2.5 mg; Pseudoephedrine Hydrochloride 60 mg (Medicamenta)
Prinopril (Bulgaria)
Pritnox (Poland)
Procaptan (Italy)
Provinace (Malaysia)
Provinace 4 mg x 3 Blister x 10 Tablet
Provinace 4 mg x 30's
Ran-Perindopril (South Africa)
Relika (Croatia (Hrvatska))
Revosyl 8
Rindolex (Slovenia)
Serperil (Turkey)
Spec Perindopril (South Africa)
Spopress (Poland)
Stoppress (Romania)
Stopress (Bulgaria, Estonia, Latvia, Lithuania)
Terc-butilaminijev (Slovenia)
Terry White Chemists Perindopril (Australia)
Tablet; Oral; Perindopril Erbumine 2 mg
Tablet; Oral; Perindopril Erbumine 4 mg
Tablet; Oral; Perindopril Erbumine 8 mg
Terry White Chemists Perindopril Arginine (Australia)
Trezen (Romania)
Vectoryl (South Africa)
Versil (Bangladesh)
Versil 6 mg Tablet (Silver Biotech (Sanify Healthcare Pvt. Ltd.))	$ 0.18
Vidotin (Czech Republic, Estonia, Latvia, Lithuania, Poland, Romania)
Vidotin 4 mg (Hungary)
Vidotin 8 mg (Hungary)
Viritin (Vietnam)
Viritin 4 (Vietnam)
Viritin 4 4 mg x 1 Blister x 30 Tablet
Zimpril
Zimpril 4mg Tablet (Zee Laboratories)	$ 0.10
Zimpril 8mg Tablet (Zee Laboratories)	$ 0.17
Zydus Perindopril (South Africa)
See 519 substitutes for Ranbapril

References

1. PubChem. "PERINDOPRIL". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
2. DrugBank. "PERINDOPRIL". http://www.drugbank.ca/drugs/DB00790 (accessed September 17, 2018).
3. MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Ranbapril are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ranbapril. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology